# OnCo record aml-idh (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/aml-idh/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "aml-idh" ;
  schema:name "IDH1- and IDH2-mutated acute myeloid leukaemia"@en ;
  schema:alternateName "IDH-mutant AML"@en, "IDH1-mutated AML"@en, "IDH2-mutated AML"@en ;
  schema:description "IDH-mutated acute myeloid leukaemia has a faulty metabolic enzyme that floods cells with a chemical that blocks maturation. Pills that shut the enzyme off, ivosidenib for IDH1 and enasidenib or olutasidenib for IDH2 and IDH1, let the leukaemia cells mature, and ivosidenib with azacitidine tripled survival in older patients."@en ;
  schema:url <https://onco.cc/cancers/aml-idh/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Isocitrate_dehydrogenase> ;
  schema:citation <https://en.wikipedia.org/wiki/Isocitrate_dehydrogenase>, <https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1411> ;
  onco:tag "subtype-page" ;
  onco:technologies <https://onco.cc/technologies/epigenetic-drugs/> ;
  onco:targets <https://onco.cc/targets/idh/> ;
  onco:terms <https://onco.cc/terms/differentiation-syndrome/>, <https://onco.cc/terms/eln-risk/>, <https://onco.cc/terms/hma/> ;
  onco:pipeline <https://onco.cc/drugs/olutasidenib/>, <https://onco.cc/drugs/venetoclax/>, <https://onco.cc/trials/myelomatch/>, <https://onco.cc/technologies/epigenetic-drugs/> ;
  onco:standardOfCare <https://onco.cc/drugs/ivosidenib/>, <https://onco.cc/drugs/azacitidine/>, <https://onco.cc/trials/agile/>, <https://onco.cc/drugs/venetoclax/>, <https://onco.cc/trials/viale-a/>, <https://onco.cc/drugs/cytarabine-7-3/>, <https://onco.cc/technologies/allogeneic-hsct/>, <https://onco.cc/drugs/ivosidenib/>, <https://onco.cc/drugs/ivosidenib/>, <https://onco.cc/drugs/olutasidenib/>, <https://onco.cc/drugs/enasidenib/>, <https://onco.cc/drugs/venetoclax/>, <https://onco.cc/technologies/allogeneic-hsct/> .